Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of LY2951742 in Episodic Cluster Headache
2015-000149-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cluster Headache (CH) comparing LY2951742 300 mg with Placebo (2 arms). Primary endpoint: Mean change in weekly cluster headache attack frequency. Started Mar 2015; status: completed.
02
Drugs
galcanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2015-000149-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000149-22.